新诊断系统性红斑狼疮的治疗目标:LLDAS与缓解同早期损伤积累减少的关联
单中心116例新诊断SLE队列显示,治疗6个月时达到临床缓解(CR)或狼疮低疾病活动状态(LLDAS)均与18个月时早期损伤积累减少独立相关。尽管CR是推荐的主要目标,LLDAS在SLE早期管理中可作为有效替代目标,且维持LLDAS或CR至12个月的患者损伤显著更少。
要点
- 治疗6个月达到CR或LLDAS均独立降低早期损伤风险。
- 维持LLDAS(含CR)至18个月者损伤显著少于未能维持者。
- LLDAS在SLE早期可作为CR之外的有效治疗目标。
核心结论
- 尽管CR被推荐为SLE主要治疗目标,LLDAS在SLE早期管理中代表有效替代。
- 应追求LLDAS和CR的维持以预防损伤。
研究设计与样本
- 单中心队列纳入116例新诊断SLE患者,评估治疗开始后6个月(T1)达到及随后12个月维持LLDAS与CR的情况。
- 随访18个月(T2)时用SLICC/ACR损伤指数记录早期损伤,行单变量和多变量分析。
主要发现
- T1时LLDAS达到率显著高于CR(42.2% vs 21.6%,P < 0.001)。
- T2时LLDAS达到率显著高于CR(46.6% vs 31.9%,P = 0.022)。
- 持续LLDAS与持续CR的重叠率为41.7%(n = 15)。
- 多变量分析中,T1达到CR(OR 0.07 [95% CI 0.01-0.59],P = 0.015)和LLDAS(OR 0.25 [95% CI 0.06-0.99],P = 0.049)均独立与早期损伤积累减少相关。
- T1达到LLDAS(含CR)并持续至T2者,损伤显著少于T1-T2间未能维持者(P = 0.003)、晚于T1达到者(P < 0.001)或从未达到者(P < 0.001)。
关键数值与推荐
- LLDAS与CR的定义及评估标准依原文所用标准,摘要未列出具体条目。
- 早期损伤用SLICC/ACR损伤指数在18个月时评估。
临床怎么用
- 对新诊断SLE患者,治疗6个月内应积极追求LLDAS或CR,并持续维持以降低早期损伤风险。
- LLDAS可作为SLE早期管理中CR未达到时的有效替代治疗目标。
局限性
- 单中心队列设计,样本量116例,结论外推需谨慎。
- 摘要未报告盲法、失访及混杂因素控制等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effect of achievement and maintenance of Lupus Low Disease Activity State (LLDAS) and clinical remission (CR) in preventing early damage accrual in patients with systemic lupus erythematosus (SLE). METHODS: In a monocentric cohort of 116 newly diagnosed SLE patients, LLDAS and CR achievement at 6 months (T1) after treatment initiation and their maintenance over the next 12 months were assessed. Early damage was recorded after 18 months of follow-up (T2) using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Univariate and multivariate analyses were performed to evaluate the association of LLDAS and CR with early damage. RESULTS: LLDAS was significantly more attained than CR both at T1 (42.2% versus 21.6% of patients; P < 0.001) and T2 (46.6% versus 31.9%; P = 0.022). The overlap rate between persistent LLDAS and persistent CR was 41.7% (n = 15). On multivariate analysis, achievement of CR (odds ratio [OR] 0.07 [95% confidence interval (95% CI) 0.01-0.59], P = 0.015) and LLDAS (OR 0.25 [95% CI 0.06-0.99], P = 0.049) at T1 were independently associated with lower accrual of early damage. Patients who achieved LLDAS (including CR) at T1 and steadily persisted in this condition until T2 developed significantly less damage compared to those who failed to maintain it during the T1-T2 interval (P = 0.003), those who achieved it later than T1 (P < 0.001), or those who had never been in this condition (P < 0.001). CONCLUSION: Although CR is recommended as the primary treatment target in SLE, LLDAS represents a valid alternative in the early stage of SLE management. LLDAS and CR maintenance should be targeted to prevent damage.
引用
- Floris A, Piga M, Perra D, et al. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage. Arthritis Care Res (Hoboken). 2020. PMID: 31600023. doi:10.1002/acr.24086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。